title: A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
authors.affiliation: Clinical Pharmacology Research Core, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Tanyifor M
authors.initials: TM
authors.lastname: Tohnya
authors.forename: Sylvia S W
authors.initials: SS
authors.lastname: Ng
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
authors.forename: John J
authors.initials: JJ
authors.lastname: Wright
authors.forename: Philip M
authors.initials: PM
authors.lastname: Arlen
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.forename: Catherine
authors.initials: C
authors.lastname: Parker
authors.forename: Jerome
authors.initials: J
authors.lastname: Zeldis
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D000284:Administration, Oral; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009362:Neoplasm Metastasis; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012107:Research Design; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide